Eli Lilly and Company, Lilly Research Laboratories, Health Safety and Environmental, Indianapolis, IN 46285, USA.
Regul Toxicol Pharmacol. 2010 Dec;58(3):369-81. doi: 10.1016/j.yrtph.2010.08.002. Epub 2010 Aug 27.
In order to determine a threshold for nongenotoxic carcinogens, the traditional risk assessment approach has been to identify a mode of action (MOA) with a nonlinear dose-response. The dose-response for one or more key event(s) linked to the MOA for carcinogenicity allows a point of departure (POD) to be selected from the most sensitive effect dose or no-effect dose. However, this can be challenging because multiple MOAs and key events may exist for carcinogenicity and oftentimes extensive research is required to elucidate the MOA. In the present study, a microarray analysis was conducted to determine if a POD could be identified following short-term oral rat exposure with two nongenotoxic rodent carcinogens, fenofibrate and methapyrilene, using a benchmark dose analysis of genes aggregated in Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and Gene Ontology (GO) biological processes, which likely encompass key event(s) for carcinogenicity. The gene expression response for fenofibrate given to rats for 2days was consistent with its MOA and known key events linked to PPARα activation. The temporal response from daily dosing with methapyrilene demonstrated biological complexity with waves of pathways/biological processes occurring over 1, 3, and 7days; nonetheless, the benchmark dose values were consistent over time. When comparing the dose-response of toxicogenomic data to tumorigenesis or precursor events, the toxicogenomics POD was slightly below any effect level. Our results suggest that toxicogenomic analysis using short-term studies can be used to identify a threshold for nongenotoxic carcinogens based on evaluation of potential key event(s) which then can be used within a risk assessment framework.
为了确定非遗传毒性致癌物质的阈值,传统的风险评估方法是确定具有非线性剂量反应的作用模式(MOA)。致癌作用的 MOA 与一个或多个关键事件(s)相关的剂量反应允许从最敏感的效应剂量或无效应剂量中选择起始点(POD)。然而,这可能具有挑战性,因为致癌作用可能存在多种 MOA 和关键事件,并且通常需要进行广泛的研究来阐明 MOA。在本研究中,进行了微阵列分析,以确定是否可以在短期口服大鼠暴露于两种非遗传毒性啮齿动物致癌物质,非诺贝特和甲吡嘧啶后,使用京都基因与基因组百科全书(KEGG)途径和基因本体论(GO)生物过程中聚集的基因的基准剂量分析来确定 POD ,这可能包含致癌作用的关键事件(s)。在 2 天内给予大鼠的非诺贝特的基因表达反应与其 MOA 一致,并且与已知的与 PPARα激活相关的关键事件一致。用甲吡嘧啶每日给药的时间反应显示出生物学复杂性,途径/生物学过程在 1、3 和 7 天内发生波;尽管如此,基准剂量值随时间保持一致。当将毒代基因组学数据的剂量反应与肿瘤发生或前体事件进行比较时,毒代基因组学的 POD 略低于任何效应水平。我们的结果表明,使用短期研究的毒代基因组学分析可以用于确定非遗传毒性致癌物质的阈值,方法是评估潜在的关键事件(s),然后可以在风险评估框架内使用这些关键事件。